×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win
BioSpace
AstraZeneca and Daiichi Sankyo's antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast...
3 days ago
Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are
Simply Wall Street
When companies post strong earnings, the stock generally performs well, just like Daiichi Sankyo Company, Limited's...
13 hours ago
AstraZeneca, Daiichi tout Enhertu trial win in earlier, broader HER2-low breast cancer
Fierce Pharma
AstraZeneca and Daiichi Sankyo's trailblazing Enhertu appears to have outdone itself. After spearheading the new HER2-low category in breast...
4 days ago
AstraZeneca and Daiichi Sankyo's Enhertu shows promise in breast cancer trial
Clinical Trials Arena
AstraZeneca and Daiichi Sankyo have announced that their therapy Enhertu has shown a statistically and clinically meaningful...
4 days ago
AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study
PMLiVE
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug conjugate...
1 day ago
Daiichi Sankyo Earnings: Company Gives Strong Guidance, Has Robust Pipeline Progression
Morningstar
Narrow-moat Daiichi Sankyo's fourth-quarter revenue grew 30% year on year, which is in line with our optimistic expectations.
6 days ago
Daiichi invests 1 bln eur near Munich to make precision cancer drugs
Reuters
Daiichi Sankyo said on Friday it would invest about 1 billion euros ($1.07 billion) to expand a site near Munich, Germany, to boost its work...
2 months ago
Daiichi Sankyo beats bid to revive multibillion-dollar ICDR claim
Global Arbitration Review
US biotech company Seagen has failed to revive an ICDR claim against Daiichi Sankyo over rights to cancer-fighting technology,...
1 month ago
FDA accepts AstraZeneca-Daiichi Sankyo's Dato-DXd BLA
Pharmaceutical Technology
The US FDA has accepted AstraZeneca and Daiichi Sankyo's BLA for datopotamab deruxtecan for breast cancer patients.
1 month ago
Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs
BioPharm International
Daiichi Sankyo is investing approximately €1 billiion (US$1.08 billion) to expand its Pfaffenhofen an der Ilm, Germany,...
2 months ago